University of Iowa News
Aug. 30, 2006
UI Study Invites Participants With Type 2 Diabetes
People ages 18 to 77 who have type 2 diabetes and are taking Avandia or Actos (also called thiazolidinediones or TZDs) are invited to participate in a University of Iowa research study on controlling blood sugar.
The study will compare the safety and effectiveness of two different doses of an investigational medicine and TZD compared to placebo (inactive pill) and TZD.
Eligible participants will randomly be assigned to one of the three study groups and will be required to make up to 20 visits to the UI Lipid Research Center. The entire study will last approximately one-and-a-half years.
Women who have the potential to become pregnant must agree to practice an effective method of birth control throughout the study.
Qualified participants will receive, at cost, physical exams and electrocardiograms, laboratory evaluation, nutrition and exercise counseling, a glucose meter for home glucose monitoring, and all study pills (TZD and investigational drug or placebo. Compensation for travel and participation also will be provided.
Nearly 555 individuals are expected to participate in this worldwide study. The UI portion of the study is led by Jennifer Robinson, M.D., associate professor of epidemiology in the UI College of Public Health and director of the UI Lipid Research Center.
For more information, call toll-free 800-887-6917 or 319-384-5046.
STORY SOURCE: University of Iowa Health Science Relations, 5137 Westlawn, Iowa City, Iowa 52242-1178
STUDY CONTACT: UI Lipid Research Center, 800-887-6917 or 319-384-5048
MEDIA CONTACT: Becky Soglin, 319-335-6660 email@example.com